Oruka Therapeutics stock maintained at Buy by TD Cowen ahead of data

TD Cowen reiterated a Buy on Oruka Therapeutics ahead of initial 16-week psoriasis data for ORKA-001 from the EVERLAST-A trial, with analysts saying >39%-49% PASI 100 efficacy could support multi-billion-dollar peak sales and >50% could imply more than $10 billion. The stock is already up 647% over the past year and trades at $69.06, near its $70.14 52-week high, with a $3.4 billion market cap. While the article highlights optimism around the long-acting dosing profile, it also notes the company remains unprofitable and may be overvalued at 7.3x book value.

Analysis

ORKA is a classic binary catalyst with the market already pricing in a meaningful probability of a best-in-class readout. The key second-order issue is not whether the first data set is “good,” but whether it is good enough to force analysts to move from optionality into a credible durability narrative; if efficacy lands merely in the Skyrizi-adjacent range, the stock may de-rate even on a positive headline because the current valuation already implies a premium for convenience and a large peak-sales outcome.

The asymmetry comes from dosing economics. A quarterly-or-annual regimen only matters if the efficacy bar is high enough to offset physician inertia and payer skepticism versus entrenched biologics; otherwise, the market will treat long-interval dosing as a nice-to-have, not a franchise re-ordering event. That makes the readout especially sensitive to PASI 100 concentration in the upper tail and to whether response durability looks clean enough to support infrequent maintenance without hidden drop-off.

Consensus appears to be missing timeline risk more than science risk. The stock can remain elevated into the catalyst, but after the print the next rerating window depends on replication, dose-selection clarity, and safety/tolerability — a months-long process, not a same-day victory lap. In other words, the tape is likely to reward a blowout and punish merely “encouraging” data because expectations have already migrated from proof-of-concept to franchise quality.

The contrarian setup is that the cleaner trade may be to own the event optionality, not the common equity outright. If the data are strong, implied upside can be harvested quickly; if the data are merely fine, the downside can be sharp because the valuation leaves little room for a normal biotech execution discount. That creates a favorable structure for defined-risk exposure rather than unhedged beta.

Key Decisions for Investors

• Buy ORKA call spreads into the May readout; prefer 1-2 month tenor with strikes centered above current spot to express upside to a blowout while capping premium outlay. Best risk/reward if PASI 100 clears the high-40s and forces a step-up in peak-sales assumptions.
• If already long ORKA common, hedge 25-50% of delta with short-dated calls or a partial sell-down ahead of the catalyst. The stock is priced for success, so a merely in-line data set could compress 15-25% in a single session.
• Event-driven pair: long ORKA / short a large-cap psoriasis incumbent over the catalyst window only if you want to express convenience disruption. The spread works best on a true efficacy-plus-dosing surprise; it should be flattened quickly if ORKA lands only near peer efficacy.
• Post-readout, buy ORKA on a pullback only if the data support repeatability and the market overreacts to near-term dilution or trial-design noise. The better entry may be 1-2 weeks after the print once the first sell-side model revisions settle.
• Do not chase the stock on an incremental beat. The risk/reward flips fast once the market starts discounting commercialization, because that shifts the debate from science to adoption speed and payer behavior, both of which usually deserve a higher discount rate.